Abstract Number: 1437 • ACR/ARP Annual Meeting 2019
Comparison of the Efficacy and Safety of Abatacept in Rheumatoid Arthritis Patients with and Without Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) is one of complication in patients with rheumatoid arthritis (RA) and its presence often has an effect on the management…Abstract Number: 63 • ACR/ARHP Annual Meeting 2018
TNF-α Blockade Incompletely Reverses Inflammatory Pulmonary Pathology in the TNF-Transgenic Mouse Model of Rheumatoid Arthritis
Background/Purpose: Interstitial lung disease (ILD) is a significant contributor to rheumatoid arthritis (RA) mortality, yet its pathogenesis remains enigmatic. One theory posits that initial inflammatory…Abstract Number: 498 • ACR/ARHP Annual Meeting 2017
Response to Abatacept of Different Patterns of Interstitial Lung Disease in Rheumatoid Arthritis. Multicenter Study of 63 Patients
Background/Purpose: Disease modifying antirheumatic drugs (DMARD) such as methotrexate (MTX), ) or antiTNFα have been implicated in exacerbation of Interstitial lung disease (ILD)of rheumatoid arthritis…Abstract Number: 2583 • ACR/ARHP Annual Meeting 2016
Abatacept in Rheumatoid Arthritis with Interstitial Lung Disease: A Multicenter Study of 55 Patients
Background/Purpose: Interstitial Lung Disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). A potential association of anti-TNFα drugs and conventional disease-modifying anti-rheumatic drugs…
ACR Meeting Abstracts